Hip bone loss is attenuated with but not daily vitamin D3: a 1-year double-blind RCT in postmenopausal women.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Few year-long vitamin D supplementation trials exist that match seasonal changes.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2 D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX], and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Circulating PTH, serum Ca, and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit.

What Was Measured

PubMed files the paper under topics including Biomarkers, Bone Density, Bone Resorption, Cholecalciferol, Fibroblast Growth Factor-23, Hip and Parathyroid Hormone.

Author keywords: BONE LOSS, BONE TURNOVER MARKERS, POSTMENOPAUSAL WOMEN, RANDOMIZED CONTROLLED TRIAL and VITAMIN D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2013 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.